Targeted Delivery and ROS-Responsive Release of Lutein Nanoassemblies Inhibit Myocardial Ischemia-Reperfusion Injury by Improving Mitochondrial Function
Pilong Shi,Yuetong Sha,Xinran Wang,Tao Yang,Jiawei Wu,Jiajun Zhou,Kai Liu,Xue Guan,Song Wang,Yongsheng Liu,Jingquan Gao,Hongli Sun,Tao Ban,Yonggang Cao
DOI: https://doi.org/10.2147/ijn.s488532
IF: 7.033
2024-11-27
International Journal of Nanomedicine
Abstract:Pilong Shi, 1, &ast Yuetong Sha, 1, &ast Xinran Wang, 1, &ast Tao Yang, 1 Jiawei Wu, 1 Jiajun Zhou, 1 Kai Liu, 1 Xue Guan, 2 Song Wang, 1 Yongsheng Liu, 1 Jingquan Gao, 3 Hongli Sun, 1 Tao Ban, 1 Yonggang Cao 1 1 Department of Pharmacology, Harbin Medical University, Heilongjiang, 163319, People's Republic of China; 2 Morphological Experiment Center, Harbin Medical University, Heilongjiang, 163319, People's Republic of China; 3 Department of Nursing, School of Medicine, Lishui University, Lishui, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yonggang Cao; Hongli Sun, Email ; Purpose: Myocardial ischemia-reperfusion injury (MI/RI) is associated with increased oxidative damage and mitochondrial dysfunction, resulting in an elevated risk of mortality. MI/RI may be alleviated by protecting cardiomyocytes from oxidative stress. Lutein, which belongs to a class of carotenoids, has proven to be effective in cardiovascular disease treatment due to its remarkable antioxidant properties, but its application is limited due to its poor stability and low bioavailability in vivo. Methods: In this study, a delivery system was developed based on distearoyl phosphatidyl ethanolamine (DSPE)-thiol-ketone (TK)-PEG2K (polyethylene glycol 2000) (abbreviated as DTP) and PCM-SH (CWLSEAGPVVTVRALRGTGSW) to deliver lutein (abbreviated as lutein@DTPP) to damaged myocardium. First, lutein, lutein@DTP, or lutein@DTPP were injected through the tail vein once a day for 3 days and then MI/RI model rats were established by exposing rats to ischemia for 45 min and reperfusion for 6 h. We employed a range of experimental techniques including qRT-PCR, Western blotting, transmission electron microscopy, immunohistochemistry, immunofluorescence, flow cytometry, immunoprecipitation, molecular docking, and molecular dynamics simulations. Results: Lutein@DTPP exhibited good myocardial targeting and ROS-responsive release. Our data suggested that lutein@DTPP effectively suppresses ferroptosis in cardiomyocytes. Mechanistically, we observed an upregulation of mouse double minute-2 (MDM2) in the hearts of MI/RI models and cardiomyocytes exposed to hypoxia/reoxygenation (H/R) conditions. In addition, NADH-ubiquinone oxidoreductase 75 kDa Fe-S protein 1 (NDUFS1) translocation from the cytosol to the mitochondria was inhibited by MDM2 upregulation. Notably, no significant variation in the total NDUFS1 expression was observed in H/R-exposed cardiomyocytes following treatment with siMDM2. Further study indicated that lutein facilitates the translocation of NDUFS1 from the cytosol to mitochondria by directly binding and sequestering MDM2, thereby improving mitochondrial function and inhibiting ferroptosis. Conclusion: Lutein@DTPP promoted the mitochondrial translocation of NDUFS1 to restore mitochondrial function and inhibited the ferroptosis of cardiomyocytes by directly binding and sequestering MDM2. Keywords: myocardial ischemia-reperfusion injury, lutein, ROS, MDM2, NDUFS1, ferroptosis Myocardial ischemia and its subsequent ischemia-reperfusion injury are significant contributors to myocardial injury and key pathophysiological processes in several cardiovascular diseases (CVDs), leading to increased healthcare costs and mortality rates. 1 Currently, therapeutic strategies for managing myocardial ischemia-reperfusion injury (MI/RI) primarily focus on protecting cardiomyocytes by removing reactive oxygen species (ROS), controlling inflammation, and limiting apoptosis. 2 Due to the substantial energy demands associated with contractile activity, the heart relies heavily on the preservation of normal mitochondrial respiration function. Emerging evidence indicates that mitochondrial dysfunction plays a crucial role in cardiomyocyte death and cardiac failure during energy-stress conditions, such as MI/RI. 3,4 Enhanced mitochondrial function ultimately enhances cell survival by aiding cardiomyocytes in coping with cellular ischemia stressors. 5 Thus, innovative cardioprotective strategies may be provided by novel therapeutics effective in mitigating mitochondrial dysfunction in MI/RI. 6,7 As the cell's power plant, mitochondria are responsible for generating adenosine triphosphate (ATP), the energy needed to support cellular life processes. 8 Under stress conditions, mitochondria regulate various biological activities, including signal transduction and metabolism. 9 The contraction and relaxation of the heart rely on a continuous supply -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology